You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical 43<br />
4.8.2 Cyramza – ramucirumab – Eli Lilly and Company 43<br />
4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical 44<br />
4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals 45<br />
4.8.5 MelCancerVac – DanDrit Biotech 46<br />
4.8.6 Xilonix – XBiotech 47<br />
4.8.7 Nintedanib – Boehringer Ingelheim 47<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/colorectal-cancertherapeutics-in-major-developed-markets-to-2020-increased-uptake-of-high-priced-drugs-to-offsetthe-impact-of-generics<br />
5 Market Forecast to 2020 49<br />
5.1 Global Market 49<br />
5.1.1 Treatment Use Patterns 49<br />
5.1.2 Market Size 49<br />
5.2 North America 50<br />
5.2.1 Treatment Use Patterns 50<br />
5.2.2 Annual Cost of Therapy 51<br />
5.2.3 Market Size 52<br />
5.3 Top Five European Markets 53<br />
5.3.1 Treatment Use Patterns 53<br />
5.3.2 Annual Cost of Therapy 55<br />
5.3.3 Market Size 56<br />
5.4 Japan 57<br />
5.4.1 Treatment Use Patterns 57<br />
5.4.2 Annual Cost of Therapy 58<br />
5.4.3 Market Size 59<br />
5.5 Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020 60
Change language